{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:59:09Z","timestamp":1788447549699,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major treatment of colorectal peritoneal carcinomatosis (CPC). The aim was to determine the disease-free survival (DFS) and overall survival (OS) of patients undergoing CRS\u2013HIPEC for CPC and factors associated with long-term survival (LTS). Methods: consecutive CPC patients who underwent CRS\u2013HIPEC at a HIPEC center between 2007 and 2021 were included. Actual survival was calculated, and Cox proportional hazards models were used to identify factors associated with OS, DFS and LTS. Results: there were 125 patients with CPC who underwent primary CRS\u2013HIPEC, with mean age of 54.5 years. Median follow-up was 31 months. Average intraoperative PCI was 11, and complete cytoreduction (CC-0) was achieved in 96.8%. Median OS was 41.6 months (6\u2013196). The 2-year and 5-year OS were 68% and 24.8%, respectively, and the 2-year DFS was 28.8%. Factors associated with worse OS included pre-HIPEC systemic therapy, synchronous extraperitoneal metastasis, and PCI \u2265 20 (p &lt; 0.05). Progression prior to CRS\u2013HIPEC was associated with worse DFS (p &lt; 0.05). Lower PCI, fewer complications, lower recurrence and longer DFS were associated with LTS (p &lt; 0.05). Conclusion: CRS and HIPEC improve OS in CPC patients but they have high disease recurrence. Outcomes depend on preoperative therapy response, extraperitoneal metastasis, and peritoneal disease burden.<\/jats:p>","DOI":"10.3390\/curroncol31070269","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T08:31:36Z","timestamp":1719563496000},"page":"3657-3668","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin"],"prefix":"10.3390","volume":"31","author":[{"given":"Kadhim","family":"Taqi","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-695X","authenticated-orcid":false,"given":"Jay","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-5349","authenticated-orcid":false,"given":"Scott","family":"Hurton","sequence":"additional","affiliation":[{"name":"Division of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-1013","authenticated-orcid":false,"given":"Cecily","family":"Stockley","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Mack","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-8361","authenticated-orcid":false,"given":"Justin","family":"Rivard","sequence":"additional","affiliation":[{"name":"Division of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walley","family":"Temple","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-8372","authenticated-orcid":false,"given":"Antoine","family":"Bouchard-Fortier","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3748\/wjg.v18.i39.5489","article-title":"Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options","volume":"18","author":"Klaver","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in the Netherlands: Nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.26574\/maedica.2019.14.3.280","article-title":"Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer","volume":"14","author":"Coco","year":"2019","journal-title":"Maedica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e100016","DOI":"10.1136\/egastro-2023-100016","article-title":"Treatment and prognosis of colorectal cancer with synchronous peritoneal metastases: 11-year single institute experience","volume":"1","author":"Qin","year":"2023","journal-title":"eGastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12957-021-02145-1","article-title":"Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: A retrospective descriptive study","volume":"19","author":"Kamada","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_10","first-page":"72","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: Survival outcomes and patient selection","volume":"7","author":"Esquivel","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/pp-2017-0003","article-title":"Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice","volume":"2","author":"Lemoine","year":"2017","journal-title":"Pleura Peritoneum."},{"key":"ref_12","first-page":"15","article-title":"Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer","volume":"38","author":"Murono","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3816\/CCC.2009.n.014","article-title":"Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: A North Central Cancer Treatment Group review of 3811 patients, N0144","volume":"8","author":"Dy","year":"2009","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2017.03.028","article-title":"Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review","volume":"114","author":"Rovers","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.21037\/jgo-20-133","article-title":"Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Recent insights from clinical studies and translational research","volume":"12","author":"Bakkers","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rovers, K.P., Bakkers, C., Simkens, G.A.A.M., Burger, J.W.A., Nienhuijs, S.W., Creemers, G.J.M., Thijs, A.M., Brandt-Kerkhof, A.R.M., Madsen, E.V.E., and Ayez, N. (2019). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: Protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5545-0"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Alyami","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.ejso.2020.07.039","article-title":"Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"46","author":"Birgisson","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?","volume":"257","author":"Malka","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clcc.2018.07.011","article-title":"Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial","volume":"17","author":"Glockzin","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1245\/s10434-023-14608-8","article-title":"Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin","volume":"31","author":"Sarfaty","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1503\/cjs.002519","article-title":"Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: A multicentre Canadian study","volume":"63","author":"Jost","year":"2020","journal-title":"Can. J. Surg."},{"key":"ref_23","first-page":"129","article-title":"Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Review of indications and outcomes","volume":"7","author":"Mogal","year":"2016","journal-title":"J. Gastrointest. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:19Z","timestamp":1760108659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070269"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070269","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}